EUVIMEDEUVIMED entdecken
Crossref

Metronomic Photodynamic Therapy With Immune Checkpoint Inhibitors Does Not Affect Nontarget Lesions

Takao Sugihara, Hironori Tsujimoto, Yujiro Itazaki, Seiichiro Fujishima, Keita Kouzu, Yoshihisa Yaguchi, Hiroyuki Horiguchi, Hideki Ueno, Yuji Morimoto

Journal of Surgical Research · 2025

DOI: 10.1016/j.jss.2025.02.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Surgical Research, 2025. Verfasst von Takao Sugihara und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, National Defense Medical College, Tokorozawa, Japan. Hauptthemen laut MEDLINE: Photochemotherapy, Immune Checkpoint Inhibitors, Colonic Neoplasms. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Immune checkpoint inhibitors (ICIs) have extended survival in various cancers, especially when combined with chemotherapy. This effect is thought to involve tumor-specific antigen release and T cell reactivation. The "abscopal effect," where radiation leads to tumor shrinkage at distant sites, may also be enhanced by ICIs, although this is not fully understood. Photodynamic therapy (PDT), a localized treatment, has shown potential for inducing abscopal effects, but no studies have investigated this in metronomic PDT (mPDT), which uses low fluence rates over extended periods. This study aimed to evaluate if mPDT exerts the abscopal effect and whether the addition of ICIs can enhance this effect. METHODS: Colon-26 tumor-bearing mice were treated with conventional (cPDT) or mPDT, with or without anti-PD-L1 antibodies. Tumor growth in target and nontarget lesions was measured, and immune cell infiltration was analyzed by flow cytometry. RESULTS: When combined with anti-PD-L1, cPDT significantly reduced tumor size in nontarget lesions and increased the infiltration of CD4+, CD8+, and CD3+ cells in these areas. In contrast, mPDT did not elicit a comparable antitumor response or promote CD4+, CD8+, and CD3+ cell infiltration in nontarget lesions. CONCLUSIONS: While cPDT combined with ICIs successfully reduced tumor size in nontarget lesion, mPDT did not, suggesting a limited capacity to induce systemic immune responses. Further research is needed to optimize mPDT for systemic cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhotochemotherapyImmune Checkpoint InhibitorsColonic NeoplasmsAnimalsMiceAdministration, MetronomicFemaleCell Line, TumorHumansPhotosensitizing AgentsB7-H1 AntigenMice, Inbred BALB CCombined Modality TherapyTumor Burden

Stichwörter der Autor:innen

Abscopal effectDistant metastasesMetronomic photodynamic therapy

Substanzen

Immune Checkpoint InhibitorsPhotosensitizing AgentsB7-H1 Antigen

Autor:innen und Institutionen

  • Department of Surgery, National Defense Medical College, Tokorozawa, Japan.
  • Department of Surgery, National Defense Medical College, Tokorozawa, Japan. Electronic address: tsujihi@ndmc.ac.jp.
  • Department of Physiology, National Defense Medical College, Tokorozawa, Japan.

Zitieren

APA

Sugihara, T., Tsujimoto, H., Itazaki, Y., Fujishima, S., Kouzu, K., Yaguchi, Y., Horiguchi, H., Ueno, H., & Morimoto, Y. (2025). Metronomic Photodynamic Therapy With Immune Checkpoint Inhibitors Does Not Affect Nontarget Lesions. Journal of Surgical Research. https://doi.org/10.1016/j.jss.2025.02.014

Vancouver

Sugihara T, Tsujimoto H, Itazaki Y, Fujishima S, Kouzu K, Yaguchi Y, et al. Metronomic Photodynamic Therapy With Immune Checkpoint Inhibitors Does Not Affect Nontarget Lesions. Journal of Surgical Research. 2025. doi:10.1016/j.jss.2025.02.014

BibTeX
@article{Sugihara2025,
  author = {Sugihara, Takao and Tsujimoto, Hironori and Itazaki, Yujiro and Fujishima, Seiichiro and Kouzu, Keita and Yaguchi, Yoshihisa and Horiguchi, Hiroyuki and Ueno, Hideki and Morimoto, Yuji},
  title = {Metronomic Photodynamic Therapy With Immune Checkpoint Inhibitors Does Not Affect Nontarget Lesions},
  journal = {Journal of Surgical Research},
  year = {2025},
  doi = {10.1016/j.jss.2025.02.014}
}
Kostenlos starten →